Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02741323 · ClinicalTrials.gov registry record · Phase 2
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
A Phase 2 study of HIV Infections and Kidney Diseases, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 10
- Study locations
NCT02741323 is a Phase 2 study of HIV Infections and Kidney Diseases that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 97 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT02741323, a Phase 2 study of HIV Infections and Kidney Diseases, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 10
- Study locations
Study Summary
Maraviroc (MVC) is a type of HIV medicine called a CCR5 inhibitor. This study will evaluate the safety and tolerability of MVC in HIV-infected adults receiving a kidney transplant.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maraviroc
Study Locations (10)
California
- UCLA HIVTR-CCR5 Non-Network CRS - Los Angeles
- UCSF HIVTR-CCR5 Non-network CRS - San Francisco
Maryland
- Univ. of Maryland HIVTR-CCR5 Non-Network CRS - Baltimore
- JHU HIVTR-CCR5 Non-Network CRS - Baltimore
Alabama
- UAB HIVTR-CCR5 Non-Network CRS - Birmingham
District of Columbia
- Georgetown HIVTR-CCR5 Non-Network CRS - Washington D.C.
Georgia
- Emory HIVTR-CCR5 Non-Network CRS - Atlanta
Illinois
- Northwestern HIVTR-CCR5 Non-Network CRS - Chicago
New York
- Mt. Sinai Med. Ctr. HIVTR-CCR5 Non-Network CRS - New York
Pennsylvania
- Univ. of Penn HIVTR-CCR5 Non-network CRS - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2022-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02741323
The ClinicalTrials.gov registry entry for NCT02741323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02741323 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Maryland, Alabama.
Frequently Asked Questions
What is clinical trial NCT02741323 about?
NCT02741323 is a clinical study titled "Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients". Maraviroc (MVC) is a type of HIV medicine called a CCR5 inhibitor. This study will evaluate the safety and tolerability of MVC in HIV-infected adults receiving a kidney transplant.
What is the current status of trial NCT02741323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2017-01-01. Estimated completion is 2022-05-10.
What conditions does trial NCT02741323 study?
This clinical trial studies the following conditions: HIV Infections, Kidney Diseases.
What interventions are being tested in trial NCT02741323?
The interventions under investigation include: Placebo (DRUG), Maraviroc (DRUG).
Who is sponsoring clinical trial NCT02741323?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02741323 being conducted?
This trial has 10 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.